Business

Ranbaxy gets U.S. FDA nod for Proxetil

NEW DELHI JUNE 4. Ranbaxy Laboratories has received the final approval to manufacture and market Cefpodoxime Proxetil for oral suspension from the U.S. Food and Drug Adminstration (FDA).

Ranbaxy plans to introduce the product once the New Jersey Federal district court decides in its favour on the preliminary injunction motion filed by Pharmacia and Upjohn Co, a company release said today.

The FDA's bio-equivalence division determined Ranbaxy's formulation of Cefpodoxime Proxetil as the bio-equivalent of a similar listed drug of Pharmacia and Upjohn Co.

The drug is prescribed to patients with mild to moderate infections causing pharyngitis or tonsillitis, community acquired pneumonia, acute chronic bronchitis, acute, uncomplicated urethral and cervical gonorrhea. — PTI

Send this article to Friends by E-Mail

Business

News: Front Page | National | Southern States | Other States | International | Opinion | Business | Sport | Miscellaneous |
Advts: Classifieds | Employment | Obituary |

Stories in this Section

• Reliance completes acquisition
• Mukesh Ambani to head IPCL
• SkodaAuto to expand dealer network
• Silverline's toll collection system
• HDFC Bank's Dubai office
• AirTel's facility for post-paid customers
• Ion Exchange's bottled water plant
• Ajanta Pharma's higher growth
• Parry Agro skips dividend
• New RBI Regional Director
• Textile sector on road to recovery: SIMA
• Power utilities to raise funds from abroad
• Ranbaxy gets U.S. FDA nod for Proxetil
• Big jump in Dr. Reddy's profit
• Exchange rates
• Stock Market Index
• Bullion rates

Copyright © 2002, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu